# Circassia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/circassia

- Industry: Pharmaceuticals
- Headquarters: Oxford, UK
- Website: www.circassia.co.uk
- Total disclosed funding: $152M
- Latest round: Series D (Sep 10, 2010)
- Investors on record: 5

## About

Circassia Limited is a specialty biopharmaceutical company, focused on developing immunotherapies to treat allergies, prevent organ transplant rejection and improve recovery from surgeries.

## Funding rounds

- Series D, Sep 10, 2010, $93M — Invesco Perpetual, Touchstone Innovations
- Series C, Dec 10, 2009, $25M — Invesco Perpetual, Touchstone Innovations, Lansdowne Partners
- Series B, Jan 28, 2008, $22M — Invesco Perpetual, Goldman Sachs Asset Management, Touchstone Innovations, Lansdowne Partners
- Series A, Jan 26, 2007, $12M — Tudor Capital, Touchstone Innovations, Lansdowne Partners

## Investors

- Tudor Capital — Series A
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A, Series B, Series C, Series D
- Lansdowne Partners (https://capitalatlas.ai/funds/lansdowne-partners) — Series A, Series B, Series C
- Invesco Perpetual — Series B, Series C, Series D
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B